Finanzen von Retractable Technologies Inc (RVP)RVPRetractable Technologies Inc

Retractable Technologies Inc (RVP) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Syringes, accounting for 80.8% of total sales, equivalent to $5.80M. Other significant revenue streams include EasyPoint Needles and Blood Cllection Products. Understanding this composition is critical for investors evaluating how RVP navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Retractable Technologies Inc maintains a gross margin of 2.65%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -51.07%, while the net margin is 39.31%. These profitability ratios, combined with a Return on Equity (ROE) of -4.84%, provide a clear picture of how effectively RVP converts its operational activities into shareholder value.

In the context of the broader market, RVP competes directly with industry leaders such as LFWD and ARAY. With a market capitalization of $17.05M, it holds a leading position in the sector. When comparing efficiency, RVP's gross margin of 2.65% stands against LFWD's 40.90% and ARAY's 30.15%. Such benchmarking helps identify whether Retractable Technologies Inc is trading at a premium or discount relative to its financial performance.

The company has experienced a significant decline in revenue, with Q1 2026 net sales of $7.2 million, down 13.3% year-over-year. Furthermore, the gross margin has been negative in recent quarters, with a gross margin of -1.03% in Q2 2025 and -11.68% in Q1 2026, indicating ongoing profitability issues.